For individuals seeking support with obesity or weight management, NICE-approved pathways exist and should be the starting point
Semaglutide-based drugs (Ozempic, Wegovy) and tirzepatide-based drugs (Mounjaro) are generally more effective for weight loss than other GLP-1 agonists like dulaglutide or liraglutide, according to comparative trial data
Avoid greasy, fried, spicy, or heavy foods
What happens when a fast tracked drug quickly moves into millions of bodies before we truly understand the long term effects
Market Competitive Landscape: Leading Companies and Strategies The global GLP-1 market is highly competitive, dominated by Novo Nordisk and Eli Lilly, whose therapies now dominate diabetes and obesity treatment
Semaglutide was initially prescribed to treat type 2 diabetes, so people with diabetes will not only benefit from its weight loss component but also from its ability to improve blood sugar control